Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
10,443
Total Claims
$2.2M
Drug Cost
679
Beneficiaries
$3,255
Cost/Patient
Risk Score Breakdown 30/100
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
-17%
Cost per patient vs peers
$3,255 vs $3,933 avg
-47%
Brand preference vs peers
27.0% vs 51.2% avg
⚠️ This provider has metrics more than 3 standard deviations above their specialty average in one or more categories.
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
Opioid Prescribing
2.3%
Opioid Rate
237
Opioid Claims
$4,814
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 2,709 claims · $2.0M
Generic: 7,322 claims · $157K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Semaglutide | 310 | $377K |
| Dulaglutide | 164 | $177K |
| Sitagliptin Phos/Metformin Hcl | 180 | $176K |
| Tirzepatide | 127 | $148K |
| Insulin Glargine,hum.Rec.Anlog | 172 | $119K |
| Insulin Aspart | 112 | $103K |
| Empagliflozin | 80 | $92K |
| Insulin Lispro | 44 | $50K |
| Insulin Degludec | 37 | $48K |
| Insulin Aspart Prot/Insuln Asp | 36 | $46K |
| Apixaban | 48 | $44K |
| Sitagliptin Phosphate | 57 | $43K |
| Insulin Lispro Protamin/Lispro | 36 | $43K |
| Dapagliflozin Propanediol | 47 | $43K |
| Insulin Aspart | 46 | $42K |
Prescribing Profile
Patient Profile
72
Avg Age
69%
Female
1.51
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About